Mymetics-Led Consortium Awarded €8.4 Million for Development of Thermo Stable and Cold-Chain Independent Vaccines

24-Apr-2015 - Mymetics Corporation announced that its subsidiary Mymetics BV in the Netherlands is leading a consortium that has been selected to receive project grants with a total value of €8.4 million. A total of €5.3 million is funded as part of Horizon 2020, the European Union research and innovation ...

Drug Development Technology: Frost & Sullivan Award goes to Imperacer

03-Nov-2008 - The 2008 European Immunoassay Frost & Sullivan Excellence in Technology Award has been awarded to Chimera Biotec. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent ...

Chimera Biotec invites scientists to the III. Immunolympics 2008

05-Jun-2008 - For the third time Chimera Biotec supports the scientific community with a contest on ultra-sensitive immunoassays, the III. Immunolympics are open. The contest seeks to find potential solutions to today's scientific challenges using ultra-sensitive immunoassays. It's the third time that ...

CNS-Diagnostics: Chimera Biotec Starts Study on Novel Biomarker Detection for Alzheimer's Disease

European Commission supports study including 11 centres from 6 European countries

13-Mar-2007 - Chimera Biotec joins the EU funded EDAR project to adapt the Imperacer(TM) platform technology for the detection of novel biomarkers for the diagnosis of Alzheimer's disease. The consortium wants to find out whether the new markers can be used to test efficacy of new drugs, thereby contributing ...

Chimera Biotec Partners with AvTech Laboratories to Provide Ultra-High Sensitive Immunoassay Technology to U.S.

14-Sep-2006 - AvTech Laboratories, a division of Eurofins Scientific, and Chimera Biotec GmbH have signed a cooperation agreement that combines Chimera's ultra-high sensitive immunoassay technology, Imperacer, with AvTech's expertise in state-of-the-art analytical services. Under the agreement, AvTech will ...

1,000 times higher sensitivity for doping testing available now

Chimera Biotec and German Sports University developed a new and extremely sensitive technology for anti-doping testing

08-Feb-2006 - Dr. Michael Adler, head of R&D at Chimera Biotec GmbH, Dortmund, Germany, and his group develop an ultra sensitive test for the detection of myostatin doping together with the team of Dr. Patrick Diel at the German Sports University, Cologne, Germany. The project, using Chimera IMPERACER ...